|
|
|
Volumn 13, Issue 1, 2010, Pages 7-9
|
|
AACR-NCI-EORTC - 21st international symposium molecular targets and cancer therapeutics - Part 1
a
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTINEOPLASTIC AGENT;
ANTISENSE OLIGONUCLEOTIDE;
BICALUTAMIDE;
BMS 833923;
CARBOPLATIN;
CBP 501;
CH 5137291;
CISPLATIN;
DOCETAXEL;
EZN 3889;
EZN 3892;
PACLITAXEL;
PEMETREXED;
REOLYSIN;
SELECTIVE ANDROGEN RECEPTOR MODULATOR;
SN 29926;
SN 29966;
SN 3000;
SN 30000;
SPC 3042;
TIRAPAZAMINE;
UNCLASSIFIED DRUG;
WITHAFERIN A;
XL 139;
ADVANCED CANCER;
ALANINE AMINOTRANSFERASE BLOOD LEVEL;
ANTINEOPLASTIC ACTIVITY;
AREA UNDER THE CURVE;
ASPARTATE AMINOTRANSFERASE BLOOD LEVEL;
CANCER CELL DESTRUCTION;
CANCER CHEMOTHERAPY;
CANCER INHIBITION;
CANCER RESEARCH;
CLINICAL TRIAL;
CONFERENCE PAPER;
DRUG BLOOD LEVEL;
DRUG DOSE COMPARISON;
DRUG DOSE ESCALATION;
DRUG DOSE REDUCTION;
DRUG EFFICACY;
DRUG ERUPTION;
DRUG HALF LIFE;
DRUG RESEARCH;
DRUG SAFETY;
FEBRILE NEUTROPENIA;
FEVER;
HUMAN;
HYPOPHOSPHATEMIA;
LUNG NON SMALL CELL CANCER;
MAXIMUM PLASMA CONCENTRATION;
MELANOMA;
MONOTHERAPY;
MYALGIA;
NONHUMAN;
PANCREATITIS;
PLEURA MESOTHELIOMA;
PROSTATE CANCER;
RECOMMENDED DRUG DOSE;
SIDE EFFECT;
SOLID TUMOR;
TIME TO MAXIMUM PLASMA CONCENTRATION;
TRIACYLGLYCEROL LIPASE BLOOD LEVEL;
ANIMALS;
ANTINEOPLASTIC AGENTS;
CLINICAL TRIALS AS TOPIC;
DRUG DELIVERY SYSTEMS;
DRUG DESIGN;
DRUGS, INVESTIGATIONAL;
HUMANS;
NEOPLASMS;
|
|
EID: 73649103765
PISSN: 13697056
EISSN: None
Source Type: Journal
DOI: None Document Type: Conference Paper |
|
Times cited : (10)
|
|
References (0)
|
